A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

December 18, 2019 updated by: Astellas Pharma Global Development, Inc.

A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis

The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and trigger(s) for treatment changes and to document healthcare resource utilization used to manage treatment-related complications.

Study Overview

Detailed Description

Each subject will be followed from the time of enrollment for a minimum of 3 years and a maximum of up to 6 years or until death, whichever comes first.

Study Type

Observational

Enrollment (Actual)

1533

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Algiers, Algeria, 16005
        • SIte
      • Algiers, Algeria, 16006
        • SIte
      • Blida, Algeria, BP 190
        • SIte
      • Buenos Aires, Argentina, 1060
        • SIte
      • Cabal, Argentina, C1120AAT
        • SIte
      • La Pampa, Argentina, 6300
        • SIte
    • New South Wales
      • Port Macquarie, New South Wales, Australia, 2444
        • SIte
      • Tweed Heads, New South Wales, Australia, 2485
        • SIte
    • South Australia
      • Kurralta Park, South Australia, Australia, 5037
        • SIte
    • Victoria
      • Parkville, Victoria, Australia, 3050
        • SIte
      • Richmond, Victoria, Australia, 3121
        • SIte
      • Wien, Austria, 1090
        • SIte
      • Caxias do Sul, Brazil, 95070-560
        • SIte
      • Santo André, Brazil, 09060-650
        • SIte
    • MG
      • Belo Horizonte, MG, Brazil, 30130-100
        • SIte
    • RS
      • Ijuí, RS, Brazil, 98700-000
        • SIte
      • Passo Fundo, RS, Brazil
        • SIte
      • Porto Alegre, RS, Brazil, 90110
        • SIte
    • SP
      • São Paulo, SP, Brazil, 01246-000
        • SIte
      • Quebec, Canada, G1R 2J6
        • SIte
    • Quebec
      • Granby, Quebec, Canada, J2G8Z9
        • SIte
      • Cali, Colombia, 76001
        • SIte
    • DC
      • Bogota, DC, Colombia, 110221
        • SIte
      • Bogotá, DC, Colombia, 111321
        • SIte
      • Cairo, Egypt, 11566
        • SIte
      • Cairo, Egypt, 11796
        • SIte
      • Cairo, Egypt, 12411
        • SIte
      • Besançon, France, 25030
        • SIte
      • Lille, France, 59037
        • SIte
      • Nimes, France, 30029
        • SIte
      • Pierre Benite, France, 69310
        • SIte
      • Poitiers, France, 86021
        • SIte
      • Saint Mande, France, 94163
        • SIte
      • Suresnes, France, 92151
        • SIte
      • Berlin, Germany, 14197
        • SIte
      • Freiburg, Germany, 79106
        • SIte
      • Hamburg, Germany, 20246
        • SIte
      • Jena, Germany, 7743
        • SIte
      • Nürtingen, Germany, 72622
        • SIte
      • Rostock, Germany, 18107
        • SIte
      • Ulm, Germany, 89075
        • SIte
      • Jakarta, Indonesia, 10430
        • SIte
      • Haifa, Israel, 31096
        • SIte
    • Zerifin
      • Beer Ya'akov, Zerifin, Israel, 70300
        • SIte
      • Brescia, Italy, 25123
        • SIte
      • Cremona, Italy, 26100
        • SIte
      • Milano, Italy, 20133
        • SIte
      • Orbassano, Italy, 10043
        • SIte
      • Anyang, Korea, Republic of, 431-070
        • SIte
      • Busan, Korea, Republic of, 602-714
        • SIte
      • Busan, Korea, Republic of, 602739
        • SIte
      • Incheon, Korea, Republic of, 405-760
        • SIte
      • Seoul, Korea, Republic of, 110-746
        • SIte
      • Seoul, Korea, Republic of, 137-701
        • SIte
      • Seoul, Korea, Republic of, 139-872
        • SIte
      • Suwon, Korea, Republic of, 442-723
        • SIte
    • BA
      • Beirut, BA, Lebanon, 116301
        • SIte
      • Beirut, BA, Lebanon, 166830
        • SIte
      • Durango, Mexico, 34000
        • SIte
      • Amsterdam, Netherlands, 1105 AZ
        • SIte
      • Nijmegen, Netherlands, 6525 GA
        • SIte
      • Christchurch, New Zealand, 8013
        • SIte
      • Tauranga, New Zealand, 3140
        • SIte
      • Tauranga, New Zealand, 622
        • SIte
    • Waikato
      • Hamilton, Waikato, New Zealand, 3204
        • SIte
      • Muscat, Oman
        • SIte
      • Lima, Peru, Lima 01
        • SIte
      • Lima, Peru, Lima 18
        • SIte
    • Lima
      • Miraflores, Lima, Peru, Lima18
        • SIte
      • Makati, Philippines, 1229
        • SIte
      • Pasig, Philippines, 1600
        • SIte
      • San Juan, Philippines, 1502
        • SIte
      • Riyadh, Saudi Arabia, 11411
        • SIte
      • Singapore, Singapore, 119228
        • SIte
      • Singapore, Singapore, 169610
        • SIte
      • Singapore, Singapore, 258499
        • SIte
      • Singapore, Singapore, 308433
        • SIte
      • Madrid, Spain, 28050
        • SIte
      • Sabadell, Spain, 8208
        • SIte
    • Barcelona
      • Vall d'Hebron 119-129, Barcelona, Spain, 8035
        • SIte
      • Kaohsiung, Taiwan, 807
        • SIte
      • Kaohsiung, Taiwan, 81362
        • SIte
      • Taichung, Taiwan, 40447
        • SIte
      • Taipei, Taiwan, 10002
        • SIte
      • Taipei, Taiwan, 11211
        • SIte
    • Taoyuan County
      • Guishan Township, Taoyuan County, Taiwan, 333
        • SIte
      • Bangkok, Thailand, 10400
        • SIte
      • Phayathai, Thailand, 10400
        • SIte
      • Songkla, Thailand, 90110
        • SIte
      • Hull, United Kingdom, HU17 8SX
        • SIte
      • London, United Kingdom, SE1 9RT
        • SIte
      • Newcastle upon Tyne, United Kingdom, NE7 7DN
        • SIte
      • Sunderland, United Kingdom, SR4 7TP
        • SIte

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

Subjects will be selected from the offices of either a medical oncologist, radiation oncologist, uro-oncologist, urologist, surgeon, or primary care physician.

Description

Inclusion Criteria:

  • Diagnosis of prostate adenocarcinoma
  • Will receive a new intervention at the time of study entry, for the treatment of:

    • Biochemical failure after initial curative-intent surgery (radical prostatectomy) or radiotherapy (external-beam radiation therapy, brachytherapy, or both) and a PSA doubling time of one year or less or a confirmed PSA of ≥ 50 ng/mL (2 consecutive values) within 6 months prior to study entry; or
    • Castration-resistant prostate cancer; or
    • Metastatic prostate cancer at initial diagnosis of prostate cancer

Exclusion Criteria:

  • Prior treatment of metastatic castration-resistant prostate cancer with systemic chemotherapy
  • Life expectancy of <1 year due to comorbidities

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Cohort 1
Subjects with biochemical failure experience after primary treatment and have high-risk disease
Cohort 2
Subjects with a medical diagnosis of castration-resistant prostate cancer
Cohort 3
Subjects with an initial diagnosis of metastatic prostate cancer

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patterns of disease management
Time Frame: up to 72 months
Description of disease assessment methods, physician referral patterns and treatments
up to 72 months
Clinical outcomes
Time Frame: up to 72 months
Evidence of disease progression and development of symptomatic disease
up to 72 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Factors influencing physician treatment decisions
Time Frame: up to 72 months
Reason/s for treatment choices and trigger/s for treatment changes
up to 72 months
Documentation of healthcare resource utilization used to manage treatment-related complications
Time Frame: up to 72 months
up to 72 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 31, 2013

Primary Completion (Actual)

November 14, 2019

Study Completion (Actual)

November 14, 2019

Study Registration Dates

First Submitted

February 18, 2014

First Submitted That Met QC Criteria

February 18, 2014

First Posted (Estimate)

February 20, 2014

Study Record Updates

Last Update Posted (Actual)

December 20, 2019

Last Update Submitted That Met QC Criteria

December 18, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe